SCHEMBL17839007

SCHEMBL17839007

Cc1cc(Cl)c2cccnc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.49
ALDH1A1 P00352 5/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
CCR1 P32246 2/20 0.46
CCR8 P51685 2/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPT P10636 4/20 0.45
HSP90AA1 P07900 4/20 0.44
LMNA P02545 4/20 0.44
MMP14 P50281 3/20 0.44
SLC40A1 Q9NP59 2/20 0.44
MEN1 O00255 2/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALOX15 P16050 2/20 0.44
ALOX12 P18054 2/20 0.44
SLC6A2 P23975 2/20 0.44
OPRK1 P41145 2/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30908289 1.00 NR4A2 (0.49) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL3454205 0.81 NR4A2 (0.49) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL3969039 0.80 ALDH1A1 (0.52) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL7712335 0.80 NR4A2 (0.67) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL29702168 0.80 NR4A2 (0.67) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL18572649 0.77 KDM4E (0.53) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL4433754 0.77 NR4A2 (0.58) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL7949840 0.77 MAPT (0.49) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL17838999 0.77 NR4A2 (0.49) NR4A2ALDH1A1L3MBTL1CCR1CCR8
SCHEMBL30393983 0.77 MAPT (0.49) NR4A2ALDH1A1L3MBTL1CCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 WO disclosed
EP-3237401-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR Pfizer Inc (US) 2017-11-01 EP disclosed
US-9738626-B2 Antagonists of prostaglandin EP3 receptor PFIZER INC. (US) 2017-08-22 US disclosed
WO-2016103097-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-30 WO disclosed
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PTGER3, PTGES3, PTGER2 NR4A2 560/4885ALDH1A1 2682/4885L3MBTL1 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.